Current Treatment Options in Gastroenterology

, Volume 3, Issue 6, pp 463–472 | Cite as

Localized hepatocellular carcinoma

  • D. Rohan Jeyarajah
Article
  • 17 Downloads

Opinion statement

Hepatocellular carcinoma (HCC) most commonly affects patients with underlying cirrhosis. Screening of cirrhotic patients can result in early detection of HCC. If the tumor is localized to the liver, the patient can be offered therapy. It is our belief that those patients with good liver function (Child-Pugh A/B or better) should be considered for surgical resection of one or two surgical segments of the liver. Otherwise, ablative measures, including radiofrequency ablation (RFA), cryotherapy, or angiographic embolization should be offered to the patient. Alternatively, direct injection of alcohol or acetic acid can result in effective ablation of the lesion, with unclear effects on long-term outcome. Chemotherapy does not appear to impact survival, but it is our belief that combined protocols may offer superior outcomes to single therapeutic interventions. Orthotopic liver transplantation (OLT) can have excellent efficacy in a very select group of patients.

Keywords

Hepatocellular Carcinoma Orthotopic Liver Transplantation Focal Nodular Hyperplasia Glycogen Storage Disease Spontaneous Bacterial Peritonitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Botelli R, Tibballs J, Hochhauser D, et al.: Ultrasound screening for hepatocellular carcinoma (HCC) in cirrhosis: the evidence for an established clinical practice. Clin Radiol 1998, 53:713–716.CrossRefGoogle Scholar
  2. 2.
    Mor E, Kaspa R, Sheiner P, Schwartz M: Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation. Ann Intern Med 1998, 129:643–653. Excellent review of HCC and options available. Provides excellent references.PubMedGoogle Scholar
  3. 3.
    Akriviadis EA, Llovet JM, Efremidis SC, et al.: Hepatocellular carcinoma. Br J Surg 1998, 85:1319–1331.PubMedCrossRefGoogle Scholar
  4. 4.
    Di Bisceglie A, Carithers Jr. R, Gores G: Hepatocellular carcinoma. Hepatology 1998, 82(1):1161–1165. Reviews epidemiology and screening guidelines for HCC.CrossRefGoogle Scholar
  5. 5.
    Ince N, Wands J: The increasing incidence of hepatocellular carcinoma. New Engl J Med 1999, 340(10):798–799. Good review of HCC.PubMedCrossRefGoogle Scholar
  6. 6.
    Collier J, Sherman M: Screening for hepatocellular carcinoma. Hepatology 1998, 27(1):1161–1165. Good review of screening techniques.Google Scholar
  7. 7.
    Schafer D, Sorrell M: Hepatocellular carcinoma. Lancet 1999, 353:1253–1257. Overall broad review of HCC and risk factors.PubMedCrossRefGoogle Scholar
  8. 8.
    Trojan J, Raedle J, Zeuzem S: Serum tests for diagnosis and follow-up of hepatocelular carcinoma after treatment. Digestion 1998, 59(suppl 2):72–74.PubMedCrossRefGoogle Scholar
  9. 9.
    Ros P, Davis G: The incidental focal liver lesio: photon, proton, or needle? Hepatology 1998, 1183–1190. Excellent review.Google Scholar
  10. 10.
    Vilgrain V, Fléjou JF, Arrivé L, et al.: Focal nodular hyperplasia of the liver: MR imaging and pathologic correlation in 37 patients. Radiology 1992, 184:699–703.PubMedGoogle Scholar
  11. 11.
    Vogl T, Hammerstingl R, Schwarz W, et al.: Superparamagnetic iron oxide—enhanced versus gadoliniumenhanced MR imaging for differential diagnosis of focal liver lesions. Radiology 1996, 198:881–887.Google Scholar
  12. 12.
    Stuart K, Tessitore J, Rudy J, et al.: A phase II trial of nolatrexed dihydroholoride in patients with advanced hepatocellular carcinoma. Cancer 1999, 86(3):410–414.PubMedCrossRefGoogle Scholar
  13. 13.
    Gebbia V, Maiello E, Serravezza G, et al.: 5-fluorouracil plus high dose levofolinic acid and oral hydroxyurea for the treatment of primary hepatocellular carcinomas: Results of a Phase II multicenter study of the Southern Italy Oncology Group (GOIM). Anticancer Res 1999, 19:1407–1410.PubMedGoogle Scholar
  14. 14.
    Leung T, Patt Y, Lau W, et al.: Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999, 5:1676–1681.PubMedGoogle Scholar
  15. 15.
    Olthoff KM, Rosove MH, Shackleton CR, et al.: Adjuvant chemotherapy improves survival after liver transplantation for hepatocellular carcinoma. Ann Surg 1995, 221:734–741.PubMedCrossRefGoogle Scholar
  16. 16.
    Pelletier G, Ducreux M, Gay F, et al.: Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. J Hepatol 1998, 29:129–134. Excellent review.PubMedCrossRefGoogle Scholar
  17. 17.
    Asahara T, Itamoto T, Katayama K, et al.: Adjuvant hepatic arterial infusion chemotherapy after radical hepatectomy for hepatocellular carcinoma—results of long-term follow-up. Hepatogastroenterology 1999, 46:1042–1048.PubMedGoogle Scholar
  18. 18.
    Tanaka K, Shimada H, Togo S, et al.: Use of transcatheter arterial infusion of anti-cancer agents with lipiodol to prevent recurrence of hepatocellular carcinoma after hepatic resection. Hepatogastroenterology, 1999 46:1083–1088.PubMedGoogle Scholar
  19. 19.
    Mazzaferro V, Regalia E, Doci R, et al.: Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis. N Engl J Med 1996, 334:693–699. Excellent review.CrossRefGoogle Scholar
  20. 20.
    Colella G, De Carlis L, Rondinara GF, et al.: Is hepatocellular carcinoma in cirrhosis an actual indication for liver transplantation? Tranplant Proc 1997, 29:492–494.CrossRefGoogle Scholar
  21. 21.
    Lau WY, Leung TWT, Ho SKW: Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 1999, 353:797–801. Interesting study.PubMedCrossRefGoogle Scholar
  22. 22.
    Jeyarajah DR, McBride M, Testa G, et al.: Hepatorenal syndrome: Combined liver-kidney transplantation versus isolated liver transplant. Transplantation 1997, 64(12):1760–1765.PubMedCrossRefGoogle Scholar
  23. 23.
    Nagasue N, Kohno H, Tachibana M, et al.: Prognostic factors after hepatic resection for hepatocellular carcinoma associated with Child-Turcotte Class B and C cirrhosis. Ann Surg 229(sn1):84–90.Google Scholar
  24. 24.
    Lau H, Man K, Fan ST, et al.: Evaluation of preoperative hepatocellular carcinoma undergoing hepatectomy. Br J Surg 1997, 84:1255–1259.PubMedCrossRefGoogle Scholar
  25. 25.
    Curley S, Izzo F, Delrio P, et al.: Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies. Ann Surg 1999, 230(1):1–8. Interesting article.PubMedCrossRefGoogle Scholar
  26. 26.
    Wong W, Patel S, Cruz F, et al.: Cryosurgery as a treatment for advanced stage hepatocellular carcinoma. Cancer 1998, 82(7):1268–1278.PubMedCrossRefGoogle Scholar
  27. 27.
    Lam CM, Yuen WK, Fan ST: Hepatic cryosurgery for recurrent hepatocellular carcinoma after hepatectomy: a preliminary report. J Surg Oncol 1998, 68:104–106.PubMedCrossRefGoogle Scholar
  28. 28.
    Cuschieri A, Bracken J, Boni L: Initial experience with laparoscopic ultrasound-guided radiofrequency thermal ablation of hepatic tumors. Endoscopy 1999, 31(4):318–321.PubMedCrossRefGoogle Scholar
  29. 29.
    Allgaier HP, Deibert P, Zuber I, et al.: Percutaneous radiofrequency interstitial thermal ablation of small hepatocellular carcinoma. Lancet 1999, 353:1676–1677.PubMedCrossRefGoogle Scholar
  30. 30.
    Jiao LR: Percutaneous radiofrequency thermal ablation for liver tumours. Lancet 1999, 354:427–428.PubMedCrossRefGoogle Scholar
  31. 31.
    Livraghi T: Percutaneous ethanol injection in hepatocellular carcinoma. Digestion 1998, 59(suppl 2):80–82.PubMedCrossRefGoogle Scholar
  32. 32.
    Castellano L, Calandra M, Blanco C, de Sio I: Predictive factors of survival and intrahepatic recurrence of hepatocellular carcinoma in cirrhosis after percutaneous ethanol injection: analysis of 71 patients. J Hepatol 1997, 27:862–870. Excellent resource.PubMedCrossRefGoogle Scholar
  33. 33.
    Yoon HK, Song HY, Sung KB, et al.: Percutaneous hot saline injection therapy: effectiveness in large hepatocellular carcinoma. J Vasc Iinterv Radiol 1999, 10:477–482.CrossRefGoogle Scholar
  34. 34.
    Ohnish K: Comparison of percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma. Hepatogastroenterology 1998, 45:1254–1258.Google Scholar
  35. 35.
    Markovic S, Gadzijev E, Stabuc B, et al.: Treatment options in western hepatocellular carcinoma: a prospective study of 224 patients. J Hepatol 29:650–659. Excellent review.Google Scholar

Copyright information

© Current Science Inc 2000

Authors and Affiliations

  • D. Rohan Jeyarajah
    • 1
  1. 1.Division of Gastrointestinal and Endocrine SurgeryUniversity of Texas Southwestern Medical SchoolDallasUSA

Personalised recommendations